Myocardial salvaging effects and mechanisms of metformin in experimental diabetes


  • Manjusha K. Borde Department of Pharmacology, MGM Medical College, Kamothe, Navi Mumbai 410209, India
  • Ipseeta Ray Mohanty Department of Pharmacology, MGM Medical College, Kamothe, Navi Mumbai 410209, India
  • Ujwala Maheshwari Department of Pathology, MGM Medical College, Kamothe, Navi Mumbai 410209, India
  • Rajesh Kumar Suman Department of Pharmacology, MGM Medical College, Kamothe, Navi Mumbai 410209, India
  • Y. A. Deshmukh Department of Pharmacology, MGM Medical College, Kamothe, Navi Mumbai 410209, India



Metformin, Isoproterenol, Streptozotocin, Myocardial infarction, Diabetes


Background: Several epidemiological studies have found that in type II diabetic patients, Metformin improves vascular function and reduces cardiovascular events and mortality by mechanisms that are not entirely attributed to its anti- hyperglycemic effects; So far the effect of Metformin on experimentally induced myocardial infarction in setting of type II diabetic rats has not been studied. The aim of the present study was to investigate potential cardioprotective effects and mechanisms of Metformin subsequent to isoproterenol induced myocardial infarction in the setting of diabetes.

Methods: Diabetes was induced with single dose of Streptozotocin (STZ): 45mg/kg ip and myocardial infarction was produced by administering isoproterenol (ISP): (85mg/kg, sc) to rats 24 and 48 h prior to sacrification (5th week). After the confirmation of diabetes on 7th day (Glucose>200mg/dl), Metformin (100 mg/kg) was administered and various parameters like anti-diabetic (Glucose, HbA1c), cardioprotective (CPK-MB, hs-CRP), metabolic (lipid profile, artherogenic potential), antioxidant (MDA) safety {pancreatic function (lipase), liver function (SGPT), kidney function (Creatinine) and histopathological indices of injury were evaluated in experimental groups.

Results: Administration of STZ-ISP resulted in a significant decrease in body weight (p<0.001), diabetic changes (increase in blood glucose, HbA1c), cardiac injury (leakage of myocardial CPK-MB), altered lipid profile, anti-inflammatory, antioxidant, lipase, SGPT, creatinine levels (p<0.01) in the Diabetic- ISP Control group rats as compared to Normal Control. Metformin (100 mg/kg) treatment demonstrated significant antidiabetic as well as myocardial salvaging effects as indicated by restoration of blood glucose, HbA1c and CPK-MB levels (p<0.001) compared to Diabetic- ISP Control group. In addition, Metformin favorably modulated the lipid parameters (total cholesterol, triglycerides, HDL, LDL), artherogenic index; antioxidant (MDA) potential, Subsequent to ISP challenge, histopathological assessment of heart, pancreas and biochemical indices of injury confirmed the cardioprotective effects of Metformin (100 mg/kg) in setting of diabetes.

Conclusions: The present study concluded that Metformin at 100 mg/kg demonstrated myocardial salvaging effects in type II diabetic rats challenged with experimental Myocardial infarction. The antioxidant, hypoglycemic, hypolipidemic and anti-inflammatory effects of Metformin may contribute to its beneficial effects.



Wang J, Song Y, Wang Q, Kralik PM, Epstein PN. Causes and characteristics of diabetic cardiomyopathy. The Review of Diabetic Studies. 2006;3(3):108-17.

Kannel WB, Mc Gee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-8.

Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the White hall study. BMJ (Clin Res Ed). 1983;287:867-70.

Ian l W, Brian N, Zaman AG. The management of acute myocardial Infarction in patients with diabetes mellitus. The British journal of diabetes and vascular disease. 2003;3(5):319-24.

Wexler ΒC. Metabolic and histopathologic changes in arteriosclerotic versus non arteriosclerotic rats following isoproterenol-induced myocardial infarction with superimposed diabetes.Metabolism. 1975;24(12):1321-37.

Bhatt SD, Bora PS, Srivastava LM. Carbohydrates, lipids and lipoproteins and islet changes in diabetes with superimposed myocardial infarction. J. Biosci. 1985;7:387-97.

Rakieten N, Rakieten ML, Nadkarni MV. Studies on the diabetogenic action of streptozotocin. Cancer Chemother Rep.1963;29:91-102.

Godarzi MO, Brier-Ash M: Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab. 2005;5:654-65.

Radziuk J, Zhang Z, Wiernsperger N, Pye S: Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes. 1997;46:1406-13.

Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. American Diabetes Association, European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.

Soraya H, Khorrami A, Garjani A, Maleki-Dizaji N, Garjani A. Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats. Pharmacological reports. 2012;64:1476-84.

Charlon V, Boucher F, Mouhieddine S, de Leiris J. Reduction of myocardial infarct size by metformin in rats submitted to permanent left coronary artery ligation. Diabetes Metab. 1988;14:591-5.

Solskov L, Lofgren B, Kristiansen SB. Metformin induces cardioprotection against Ischaemia/ reperfusion injury in the rat heart 24 h after administration. Basic Clin Pharmacol Toxicol. 2008;103:82-7.

Zhao JL, Fan CM, Yang YJ, You SJ, Gao X, Zhou Q. Chronic pretreatment of metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction. Cardiovasc Ther. 2013;31:60-4.

Scarpello JHB, Howlett HC. Metformin therapy and clinical uses. Diabetes Vasc Dis Res. 2008;5:157-67.

Golay A. Metformin and body weight. Int J Obes. 2008;32:61-72.

Tripathi P, Gupta PP, Lal VK. Effect of Co-administration of Allium sativum extract and Metformin on Blood glucose of Streptozotocin induced diabetic rats. J Intercult Ethnopharmacol. 2013;2(2):81-4.

Gabbay KH. Glycosylated hemoglobin and diabetic control. New England Journal Medicine. 1976;95:443-54.

Shamim A, Mahmood T, Siddiqui HH, Bagga P, Roy S. Effect of Tinosporacordifolia (Guduchi) root extract on cardiotoxicity in streptozotocin induced diabetic rats. Asian Journal of Biomedical and Pharmacutical Sciences. 2015;5(45):12-9.

Kakadiya J. Investigate the effect of hesperidin on serum diabetes marker, lipid profile and lipid metabolizing enzymes in experimentally induced myocardial infarction in diabetes in rats International Journal of Biological & Pharmaceutical Research. 2010;1(1):37-42.

Stalin C. Evaluationof antidiabetic activity of methanolic leaf extract of ficus carica in alloxan -induced diabeticrats. Asian Journal of Pharmaceutical and Clinical Research.1012;5(3):85-7.

Xie Z, Lau K, Eby B. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011;60:1770-8.

Rodrigues BH, Xiang, Mc Neill JH. Effect of Lcarnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes. 37;1988:1358-64.

Batchuluun B, Sonoda N, Takayanagi R, Inoguchi T. The Cardiovascular Effects of Metformin: Conventional and New Insights. J Endocrinol Diabetes Obes. 2014;2(2):1035.

Verma S, McNeill JH. Metformin improves cardiac function in isolated streptozotocin- diabetic rat hearts. Am J Physiol. 1994;266:H714-9.

Santana LF, Sa MF, Ferriani RA, Moura MD, Foss MC, Reis RM. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol. 2004;19:86-96.

Wulffele MG, Kooy A, Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review J Intern Med. 2004;256:1-14.

Erejuwa OO. Glibenclamide or Metformin Combined with Honey Improves Glycemic Control in Streptozotocin-Induced Diabetic Rats. International journal of biological science. 2011;7(2):244-52.

Harris EH: Elevated liver function tests in type 2 diabetes. Clin Diabetes. 2005;23:115-9.

Travlos GS, Morris RW, Elwell MR, Duke A, Resenblum S, Thompson MB. Frequency and relationships of clinical chemistry and liver and kidney histopathology findings in 13-week toxicity studies in rats. Toxicology.1996;107:17-29.

Sobha. Evaluation of antidiabetic potential of nymphaea nouchali burm. F. seeds in stz - induced diabetic rats. International journal of pharmacy and pharmaceutical sciences. 2014;6(4):536-41.




How to Cite

Borde, M. K., Mohanty, I. R., Maheshwari, U., Suman, R. K., & Deshmukh, Y. A. (2016). Myocardial salvaging effects and mechanisms of metformin in experimental diabetes. International Journal of Basic & Clinical Pharmacology, 5(2), 341–349.



Original Research Articles